Skip to content
Open access

Machine Learning-Guided Classification of Druggable Pockets and Phylogenetic Druggability Transfer Across the Human Kinome

Sep 2026 · bioRxiv · 0 citations
Biology

TL;DR

A machine learning-guided structural atlas of 11,945 kinase-inhibitor complexes is constructed and it is demonstrated that evolutionary proximity is a statistically significant predictor of shared allosteric pocket accessibility, making drug discovery more efficient.

Abstract

Protein kinases are among the most intensively pursued therapeutic targets in oncology and beyond, yet selectivity remains largely unsolved; around 536 Manning kinase domains share a conserved ATP-binding pocket, making it difficult to target one without hitting others. Allosteric binding modes which exploit conformational states unique to individual kinases or narrow kinase subfamilies offer a principled route to selectivity. Yet the absence of a kinome-wide structural landscape of these pockets limits their translational potential. Here we construct a machine learning-guided structural atlas of 11,945 kinase-inhibitor complexes, training an Extra Trees classifier on pocket residue interaction with ligand to assign all seven canonical binding modes and resolve allosteric subclasses with pharmacological precision. Our structural analysis reveals that approximately 303 Manning kinase domains have known inhibitors bound to them, representing ∼56.5% of the Manning kinase domain; of these, only 26% (78 kinases) are targeted by non-ATP-competitive allosteric inhibitors, indicating substantial unexplored pharmacological space. Integrating these classifications with the Manning kinome phylogeny, we demonstrate that evolutionary proximity is a statistically significant predictor of shared allosteric pocket accessibility. Because a functionally similar target has similar conformational dynamics and similar druggable pockets, ‘phylogenetic druggability transfer’ can act as a strong signal for identifying whether a given kinase can be targeted using an allosteric inhibitor or not. In addition, this work repositions the kinome phylogeny as a map of pharmacological opportunity and provides a reusable predictive framework for drug discovery programs - including orthosteric, allosteric, covalent, bifunctional inhibitors, and chemical degrader - across the understudied kinome. Significance Statement Most kinase drugs bind to pocket shared across the kinome, making selectivity difficult. Allosteric pockets are more selective, but their presence and accessibility are not understood across kinome. Testing a candidate against a specific binding mode requires a dedicated assay, which is expensive and time consuming, and wasted effort if that pocket is not actually accessible. We classified thousands of kinase structures by binding mode and mapped them onto the kinome phylogenetic tree. Closely related kinases often share the same druggable pockets, so this map allows us to predict likely pockets in related kinases, helping prioritize assays and identify repurposing opportunities, making drug discovery more efficient.

Read PDF

Similar papers

Review Aug 2026

Beyond the ATP-binding pocket: emerging strategies in kinase targeting from allosteric inhibition to targeted protein degradation.

The structural and medicinal chemistry principles underlying (i) allosteric inhibition and (ii) proximity-induced degradation are summarized, with an emphasis on design logic, structure-activity relationships, and key liabilities in the beyond rule of five space.

Mei Zhou, Linshan Li, Xiao-Juan Tang et al. · 0 citations
Open access Aug 2026

Conservation and divergence in the allosteric architectures of five human protein kinases

The activity and abundance of >160,000 variants are quantify the activity and abundance of >160,000 variants to construct complete maps of the energetic and allosteric architectures of five human kinase domains: SRC, FGR, JNK2/MAPK9, ZAK/MAP3K20, and TSSK2.

Carla Folgado, Antoni Beltran, Ben Lehner · 0 citations
Review Open access Sep 2026

Drug Repositioning in Kinase Inhibitor Discovery for Cancer Therapy

Repurposing of existing drugs has emerged as a time- and cost-effective strategy in oncology drug discovery. Given the critical role of dysregulated kinase signaling in cancer, kinase-focused repurposing strategies have attracted considerable interest. This approach encompasses both “target hopping” between different k...

Qian-Ran Sun, Xiao-Cong Pang, Wen-Wu Liu · 0 citations
Open access Aug 2026

PAM-DB: Revealing Protein Activation Mechanisms for Next-Generation Rational Drug Discovery

A structural database that systematically maps the complete activation trajectories of pharmaceutically relevant targets, encompassing TS, IS, and all connecting conformational ensembles is presented, offering multiple strategic advantages for drug discovery.

Xiaohong Zhu, Xiangyu Li, Yaning Hou et al. · 0 citations
Aug 2026

Decoding MLK4 Inhibition with Interpretable Machine Learning: Identification of a Novel Dihydroimidazopyridine-Based Promising Lead Compound

These findings introduce H_1 as a computationally prioritized, putative MLK4-binding lead and provide a hypothesis-generating framework for MLK4-targeted scaffold prioritization, while recognizing that experimental activity and kinome selectivity profiling remain necessary before H_1 can be described as a confirmed MLK...

Afnan A. Alzaghari, S. Daoud, Husam Nassar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.